Salt Lake City, UTNCT07436793Now EnrollingIRB Ready

Endometrial Endometrioid Adenocarcinoma Clinical Trial in Salt Lake City, UT

Access cutting-edge endometrial endometrioid adenocarcinoma treatment through this clinical trial at a research site in Salt Lake City. Study-provided care at no cost to qualified participants.

Sponsored by New Mexico Cancer Research Alliance

Quick Self-Assessment

See if you qualify for this Salt Lake City location

Preparing your pre-screening questions…

Expert Care in Salt Lake City

Access endometrial endometrioid adenocarcinoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related endometrial endometrioid adenocarcinoma treatment provided free

Apply for This Salt Lake City Location

Check if you qualify for this endometrial endometrioid adenocarcinoma clinical trial in Salt Lake City, UT

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Salt Lake City

    Convenient for UT residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Salt Lake City site if eligible
  4. 4Begin participation

About This Endometrial Endometrioid Adenocarcinoma Study in Salt Lake City

This phase II trial tests compares the effect of progestins, megestrol acetate to micronized progesterone, in treating patients with endometrial cancer and precancers of the uterus (atypical endometrial hyperplasia) before surgery. Progestins, similar to the natural hormone progesterone, are approved drugs used in birth control and hormone replacement pills, and some can treat uterine endometrial cancers. In the initial comparison of this rotating umbrella trial, megestrol acetate, a progestin, will be compared to micronized progesterone, a form of natural progesterone that is a hormone produced by body normally. Hormone therapy using megestrol acetate and micronized progesterone may be effective in treating patients with endometrial cancer or atypical endometrial hyperplasia before surgery, and understanding the tissue effects of each agent on the malignant endometrium will uncover novel mechanistic and biomarker data to understand how best to advanced hormone therapy for endometrial cancer.

Sponsor: New Mexico Cancer Research Alliance

Who Can Participate

Inclusion Criteria

Patients must have a histologically proven diagnosis of endometrioid endometrial adenocarcinoma by endometrial curettage or biopsy within 8 weeks prior to registration. Pathology reports should document adequate tissue from the biopsy and slides should be reasonable determined to be obtainable by the study team for study use
History/physical examination within 42 +/- 5 days of planned surgical procedure (18-21 days from day 1)
The trial is open only to women with primary endometrioid adenocarcinoma of the uterine corpus (all histologic grades and stages) who are planned and appropriate for primary surgical treatment to include removal of the uterine corpus via any surgical modality. The patient must be considered a suitable surgical candidate
Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, 2, or 3 within 28 days prior to registration
Formalin-fixed, paraffin-embedded tumor tissue from the biopsy or curettage must be reasonably deemed available for submission along with the corresponding pathology report
Platelets ≥ 100,000/μl
Granulocytes (absolute neutrophil count \[ANC\]) ≥ 1,500/μl
Creatinine ≤ 1.6 mg/dl
Serum glutamic-pyruvic transaminase (SGPT) (alanine transaminase \[ALT\]) ≤ 3 x upper limits of normal
Bilirubin within institutional normal limits
The patient must provide study-specific informed consent and authorization permitting release of personal health information prior to study entry
Any patients of childbearing potential must have a negative pregnancy test

Exclusion Criteria

Patients with any non-endometrioid histology (such as serous, clear cell, or carcinosarcoma or mixed)
Patients who have received prior progestin or anti-estrogen therapy during the 3 months before the diagnosis of endometrioid adenocarcinoma of the uterine corpus is established. Estrogen therapy alone is allowed
Patients with ECOG performance status of 4
Patients with history of deep venous thrombosis or pulmonary embolism within the past 2 years or ongoing thromboembolic disorders
Patients who have previously received systemic, radiation or other treatment for uterine cancer
Patients for whom formalin-fixed, paraffin-embedded tumor tissue from the biopsy or curettage is scant or unavailable
Patients with a suspected or known peanut allergy
Patients with serious comorbidities or gastrointestinal obstruction that precludes taking oral medications or have malabsorptive disease

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Salt Lake City?

Yes, this clinical trial (NCT07436793) has an active research site in Salt Lake City, UT that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Endometrial Endometrioid Adenocarcinoma Treatment Options in Salt Lake City, UT

If you're searching for endometrial endometrioid adenocarcinoma treatment options in Salt Lake City, UT, this clinical trial (NCT07436793) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Salt Lake City research site is actively enrolling participants for this clinical trial. You'll receive care from experienced endometrial endometrioid adenocarcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all endometrial endometrioid adenocarcinoma clinical trials near you to find additional studies recruiting in your area.

More Alzheimers Disease Trials in Salt Lake City, UT

See all alzheimers disease clinical trials recruiting in Salt Lake City — not just this study.

Browse Alzheimers Disease Trials in Salt Lake City →

Browse More Trials by Condition

Alzheimers Disease TrialsEssential Tremor TrialsAtopic Dermatitis TrialsOsteogenesis Imperfecta TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Salt Lake City?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Salt Lake City, UT